You are here:

Forthcoming Submission: nusinersen (Spinraza)

Indication: Treatment of 5q spinal muscular atrophy.

Drug Details

Drug Name: nusinersen (Spinraza)
Drug Manufacturer: Biogen Idec Ltd
BNF Category:
Submission type: Full submission
Patient Interest Group
Submission Deadline:
5/02/2018
SMC Meeting Date: Q2 2018
Advice Due: Q2 2018

Back